NCT04565756View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of EXN407

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

October 25, 2022

Study Completion Date

November 29, 2022

Conditions
Diabetic Macular Edema
Interventions
DRUG

EXN407

EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.

Trial Locations (11)

2000

Sydney Eye Hospital/Save Sight Institution, Sydney

2109

Macquarie University, Macquarie

2135

Strathfield Retina Clinic, Sydney

2150

Marsden Eye Specialists, Parramatta

2298

Newcastle Eye Hospital Foundation, Waratah

3002

Centre for Eye Research Australia (CERA), Melbourne

3146

Retinology Institute, Melbourne

4102

Princess Alexandra Hospital, Woolloongabba

5000

Adelaide Eye and Retina Centre, Adelaide

6009

Lions Eye Institute, Nedlands

Unknown

Sydney Retina Clinic & Day Surgery, Sydney

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Exonate Limited

INDUSTRY

NCT04565756 - A Study to Evaluate the Safety and Tolerability of EXN407 | Biotech Hunter | Biotech Hunter